Vifor Pharma AG (VIFN.SW) WACC Analysis

As of May 28, 2025, Vifor Pharma AG (VIFN.SW) carries a Weighted Average Cost of Capital (WACC) of 5.3%. WACC reflects the blended rate Vifor Pharma AG must pay to both equity and debt holders.

Within that, the cost of equity is 4.3%, the cost of debt is 4.0%, and the effective tax rate is 9.9%.

Breakdown of WACC Components

• Long-term bond rate: 1.0% – 1.5%
• Equity market risk premium: 5.1% – 6.1%
• Adjusted beta: 0.66 – 0.74
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 0.05

What It Means for Investors

With a selected WACC of 5.3%, Vifor Pharma AG must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.